https://www.profitconfidential.com/stock/medtronic-plc-mdt-stock-is-poised-to-explode-higher/
Medtronic PLC: MDT Stock Is Poised to Explode Higher
Alessandro Bruno, BA, MA
Profit Confidential
2016-08-27T05:00:56Z
2016-08-31 11:45:00 biotechbiotech stockmedtechMedtronicMedtronic PLCNYSE:MDTMDT stock. Medtronic stockMedtronic PLC (NYSE:MDT) stock has surged, but it still has major upside potential.
Stock
https://www.profitconfidential.com/wp-content/uploads/2016/08/Medtronic-PLC-300x200.jpg Medtronic PLC (NYSE:MDT) is a company with few rivals from other healthcare stocks. It supplies medical equipment, invests in acquisitions, and conducts research and development. Everything Medtronic does points to continuous growth. It’s no wonder that MDT stock has gained 11.65% year-to-date.
Medtronic boasted a net income of $1.44 billion for its first financial quarter of 2016. In the critical earnings per share (EPS) department, Medtronic gained 15%, or $1.03 per share. That was just slightly higher than the consensus of $1.01 per share, which perhaps explains why Medtronic stock has been trading flat in the past few days. Yet this flat course is unusual for MDT, which is usually seen taking off on any given chart.

More Upside for Medtronic Stock?

MDT stock has gained no less than 151% in a nice steady climb. The company has not given any indication that this boom cycle is coming to a close anytime soon. Medtronic’s guidance is the stuff that investors want to hear all the time; for the entire 2016–2017 financial year, the EPS grew from 12% to 16% and revenues increased five percent to six percent.
But there’s plenty more to Medtronic stock than the earnings. Medtronic’s revenue growth has no doubt benefited when it bought its competitor, Covidien Ltd (NYSE:COV), for $42.9 billion in 2014. This enabled MDT to move its corporate headquarters to Ireland and save on taxes. Indeed, in Ireland, where Covidien is based, the tax rate on profits (12.5%) is much lower than in the U.S. (35%).
Thanks to this acquisition, not only did Medtronic absorb a competitor, it gained access to a market of over 150 countries, dominating the manufacturing and sales of orthopedic and cardiovascular devices, as well as surgical instruments. The tax savings are just a bonus. It was essentially Medtronic that set the path for other pharma giants in search of profits to follow. Pfizer tried to adopt this strategy by throwing its sights on the British AstraZeneca plc (LON:AZN). This may not be “morally superior.” Still, if you ask shareholders whether they need more morality or more profits in their life, I wager that profits win 99 times out of 100.
But Medtronic was mindful about that minor one percent in a rare display of management sophistication. Sensitive to the debate around corporate governance and staying ahead of the curve, rather than staying merely within it, Medtronic has maintained its commitment to the United States by pledging to invest $10.0 billion over the next decade at home. Medical technology is crucial for the U.S. economy, so investors can rest assured that Medtronic’s promises are not empty words. In the biotech sector, it’s not hard to run into $10.0 billion or higher acquisitions.
Earlier in the week, Medtronic completed the acquisition of HeartWare International Inc (NASDAQ:HTWR)—a pioneer in developing new treatments for cardiovascular diseases—for about $1.1 billion. While addressing medical needs and, by all accounts operating within the medical sector, Medtronic has significant advantages, especially at its current slightly devalued price compared to biotech firms. It doesn’t have the same risk of failure.
A failure for Medtronic can be addressed at the drawing board. A failure at a biotech can mean millions of dollars down the drain and the deletion of years of work and investment. Meanwhile, Medtronic also benefits from operating in the medical sector, marked by the same relentless demand stemming from people’s innate desire to survive, improve their health, or look better. Indeed, Medtronic has an important market in designing and selling tools for surgery targeting obesity. (Source: “Medtronic launches bariatric surgery tool to enable more consistent procedures,” FierceBiotech, June. 9, 2015.)

The Bottom Line on MDT Stock

Medtronic develops devices that are engineered with a much higher probability of success than a biotech firm. Biotech firms invest in developing new and often highly welcome drugs, but—more often than not—clinical trials fail, or the side effects of a given drug outweigh its benefits. Medtronic, meanwhile, relies more on engineering than biology. That simply means it faces fewer and more controllable risks.
If you are thinking about MDT stock, note that there are other companies operating and profiting within the biotech and healthcare industries, making millions of dollars for early investors. Read our healthcare industry analyst’s latest report: “This Device to Slash Your Health Insurance Bills by up to 74%?” Click here now to get the full story.

Medtronic PLC: MDT Stock Is Poised to Explode Higher

By Alessandro Bruno, BA, MA Published : August 27, 2016

Medtronic PLC (NYSE:MDT) is a company with few rivals from other healthcare stocks. It supplies medical equipment, invests in acquisitions, and conducts research and development. Everything Medtronic does points to continuous growth. It’s no wonder that MDT stock has gained 11.65% year-to-date.

Medtronic boasted a net income of $1.44 billion for its first financial quarter of 2016. In the critical earnings per share (EPS) department, Medtronic gained 15%, or $1.03 per share. That was just slightly higher than the consensus of $1.01 per share, which perhaps explains why Medtronic stock has been trading flat in the past few days. Yet this flat course is unusual for MDT, which is usually seen taking off on any given chart.

More Upside for Medtronic Stock?

MDT stock has gained no less than 151% in a nice steady climb. The company has not given any indication that this boom cycle is coming to a close anytime soon. Medtronic’s guidance is the stuff that investors want to hear all the time; for the entire 2016–2017 financial year, the EPS grew from 12% to 16% and revenues increased five percent to six percent.

But there’s plenty more to Medtronic stock than the earnings. Medtronic’s revenue growth has no doubt benefited when it bought its competitor, Covidien Ltd (NYSE:COV), for $42.9 billion in 2014. This enabled MDT to move its corporate headquarters to Ireland and save on taxes. Indeed, in Ireland, where Covidien is based, the tax rate on profits (12.5%) is much lower than in the U.S. (35%).

Thanks to this acquisition, not only did Medtronic absorb a competitor, it gained access to a market of over 150 countries, dominating the manufacturing and sales of orthopedic and cardiovascular devices, as well as surgical instruments. The tax savings are just a bonus. It was essentially Medtronic that set the path for other pharma giants in search of profits to follow. Pfizer tried to adopt this strategy by throwing its sights on the British AstraZeneca plc (LON:AZN). This may not be “morally superior.” Still, if you ask shareholders whether they need more morality or more profits in their life, I wager that profits win 99 times out of 100.

But Medtronic was mindful about that minor one percent in a rare display of management sophistication. Sensitive to the debate around corporate governance and staying ahead of the curve, rather than staying merely within it, Medtronic has maintained its commitment to the United States by pledging to invest $10.0 billion over the next decade at home. Medical technology is crucial for the U.S. economy, so investors can rest assured that Medtronic’s promises are not empty words. In the biotech sector, it’s not hard to run into $10.0 billion or higher acquisitions.

Earlier in the week, Medtronic completed the acquisition of HeartWare International Inc (NASDAQ:HTWR)—a pioneer in developing new treatments for cardiovascular diseases—for about $1.1 billion. While addressing medical needs and, by all accounts operating within the medical sector, Medtronic has significant advantages, especially at its current slightly devalued price compared to biotech firms. It doesn’t have the same risk of failure.

A failure for Medtronic can be addressed at the drawing board. A failure at a biotech can mean millions of dollars down the drain and the deletion of years of work and investment. Meanwhile, Medtronic also benefits from operating in the medical sector, marked by the same relentless demand stemming from people’s innate desire to survive, improve their health, or look better. Indeed, Medtronic has an important market in designing and selling tools for surgery targeting obesity. (Source: “Medtronic launches bariatric surgery tool to enable more consistent procedures,” FierceBiotech, June. 9, 2015.)

The Bottom Line on MDT Stock

Medtronic develops devices that are engineered with a much higher probability of success than a biotech firm. Biotech firms invest in developing new and often highly welcome drugs, but—more often than not—clinical trials fail, or the side effects of a given drug outweigh its benefits. Medtronic, meanwhile, relies more on engineering than biology. That simply means it faces fewer and more controllable risks.

Dear Reader: There is no magic formula to getting rich. Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis. We are 100% independent in that we are not affiliated with any bank or brokerage house. Information contained herein, while believed to be correct, is not guaranteed as accurate. Warning: Investing often involves high risks and you can lose a lot of money. Please do not invest with money you cannot afford to lose. The opinions in this content are just that, opinions of the authors. We are a publishing company and the opinions, comments, stories, reports, advertisements and articles we publish are for informational and educational purposes only; nothing herein should be considered personalized investment advice. Before you make any investment, check with your investment professional (advisor). We urge our readers to review the financial statements and prospectus of any company they are interested in. We are not responsible for any damages or losses arising from the use of any information herein. Past performance is not a guarantee of future results. All registered trademarks are the property of their respective owners.